Condition (MeSH)
Caliciviridae Infections
ClinicalTrials.gov lists 19 trials for Caliciviridae Infections or a narrower condition beneath it. Vaxart has the most among industry and government lead sponsors, with 8.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
19 of the 19 trials are tagged with Caliciviridae Infections itself; the rest are tagged with a narrower condition beneath it.
When did Caliciviridae Infections trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2023 | 3 |
| 2022 | 1 |
| 2021 | 4 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 1 |
| 2014 | 1 |
| 2011 | 1 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Caliciviridae Infections trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 9 |
| Phase 1/2 | 2 |
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Not applicable | 2 |
| Observational | 2 |
How many Caliciviridae Infections trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Completed | 14 |
| Terminated | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Caliciviridae Infections trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Vaxart | 8 |
| National Vaccine and Serum Institute, China | 3 |
| InThera Inc. Korea | 1 |
| Romark Laboratories L.C. | 1 |
| WCCT Global | 1 |
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| VXA-G1.1-NN | 6 |
| VXA-G2.4-NS | 3 |
| VXA G1.1 NN-T | 1 |
| Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose | 1 |
| Norovirus Bivalent (GI.1 / GII.4) Vaccine（low） | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Caliciviridae Infections trials report? (4)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| COVID-19 Pneumonia | 1 | 1 |
| Cellulitis | 1 | 1 |
| Deep vein thrombosis | 1 | 1 |
| Hospitalization | 1 | 1 |
Which publications cover Caliciviridae Infections? (40)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody Levels With GI.1 Histo-Blood Group Antigen-Blocking Antibody Levels. | The Journal of infectious diseases | 2024 | Yes |
| Interferon-Driven Immune Dysregulation in Common Variable Immunodeficiency-Associated Villous Atrophy and Norovirus Infection. | Journal of clinical immunology | 2023 | Yes |
| Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model Inoculum. | The Journal of infectious diseases | 2022 | Yes |
| Epidemiology of Norovirus in the First 2 Years of Life in an Australian Community-based Birth Cohort. | The Pediatric infectious disease journal | 2022 | Yes |
| A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine. | Frontiers in immunology | 2022 | Yes |
Showing 5 of 40 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.